{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:13:29Z","timestamp":1721787209366},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/mph.0b013e31822ec296","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:24:52Z","timestamp":1371158692000},"page":"96-100","source":"Crossref","is-referenced-by-count":3,"title":["Pretransplant Conditioning With Campath-1H (Alemtuzumab) in Pediatric Matched Unrelated Hematopoietic Stem Cell Transplants"],"prefix":"10.1097","volume":"34","author":[{"given":"Amulya A.","family":"Nageswara Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riten","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaf","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia A.","family":"Gourde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilmarie","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakila P.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210227","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1705885","article-title":"Acute graft-versus-host disease in children.","volume":"41","author":"Jacobsohn","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R2-5-20210227","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/15258160050079407","article-title":"Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors.","volume":"9","author":"Ferrara","year":"2000","journal-title":"J Hematother Stem Cell Res"},{"key":"R3-5-20210227","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1034\/j.1399-3046.2001.005004285.x","article-title":"Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation.","volume":"5","author":"Remberger","year":"2001","journal-title":"Pediatr Transplant"},{"key":"R4-5-20210227","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/146532401753174098","article-title":"The CD52 antigen and development of the CAMPATH antibodies.","volume":"3","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"key":"R5-5-20210227","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V100.5.1715.h81702001715_1715_1720","article-title":"Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.","volume":"100","author":"Buggins","year":"2002","journal-title":"Blood"},{"key":"R6-5-20210227","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood.V88.12.4684.bloodjournal88124684","article-title":"Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils.","volume":"88","author":"Elsner","year":"1996","journal-title":"Blood"},{"key":"R7-5-20210227","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath-1H antibody on human hematopoietic progenitors in vitro.","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"key":"R8-5-20210227","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/146532400539008","article-title":"Impact on T-cell depletion and CD34 cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.","volume":"2","author":"Williams","year":"2000","journal-title":"Cytotherapy"},{"key":"R9-5-20210227","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.bmt.1702477","article-title":"CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.","volume":"26","author":"Hale","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R10-5-20210227","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/146532401753174025","article-title":"In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.","volume":"3","author":"Kottaridis","year":"2001","journal-title":"Cytotherapy"},{"key":"R11-5-20210227","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbmt.2007.01.076","article-title":"The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.","volume":"13","author":"Shah","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R12-5-20210227","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/146532401317070899","article-title":"Pharmacokinetics of CAMPATH-1H in BMT patients.","volume":"3","author":"Rebello","year":"2001","journal-title":"Cytotherapy"},{"key":"R13-5-20210227","first-page":"53","article-title":"Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.","volume":"1","author":"Apperley","year":"1986","journal-title":"Bone Marrow Transplant"},{"key":"R14-5-20210227","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2007.02.011","article-title":"Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.","volume":"13","author":"Das-Gupta","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R15-5-20210227","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"R16-5-20210227","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R17-5-20210227","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","article-title":"How I treat refractory acute GVHD.","volume":"109","author":"Deeg","year":"2007","journal-title":"Blood"},{"key":"R18-5-20210227","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/bbmt.2002.v8.pm11939605","article-title":"Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment.","volume":"8","author":"Arai","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R19-5-20210227","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.2005.06.130","article-title":"Pentostatin in steroid-refractory acute graft-versus-host disease.","volume":"23","author":"Bolanos-Meade","year":"2005","journal-title":"J Clin Oncol"},{"key":"R20-5-20210227","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/pbc.20648","article-title":"Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.","volume":"49","author":"Rodriguez","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R21-5-20210227","first-page":"405","article-title":"The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease.","volume":"91","author":"Greinix","year":"2006","journal-title":"Haematologica"},{"key":"R22-5-20210227","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.tp.0000214462.63943.14","article-title":"Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.","volume":"81","author":"Ringden","year":"2006","journal-title":"Transplantation"},{"key":"R23-5-20210227","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/146532401753173981","article-title":"CAMPATH-1 antibodies in stem-cell transplantation.","volume":"3","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"key":"R24-5-20210227","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.bbmt.2006.07.011","article-title":"Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.","volume":"12","author":"Kennedy-Nasser","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R25-5-20210227","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2008.08.010","article-title":"Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.","volume":"14","author":"Kennedy-Nasser","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R26-5-20210227","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood.V91.8.3079.3079_3079_3083","article-title":"Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants: CAMPATH users.","volume":"91","author":"Hale","year":"1998","journal-title":"Blood"},{"key":"R27-5-20210227","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1200\/JCO.2004.02.189","article-title":"Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.","volume":"22","author":"Eapen","year":"2004","journal-title":"J Clin Oncol"},{"key":"R28-5-20210227","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2002-02-0377","article-title":"Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery.","volume":"100","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"R29-5-20210227","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bmt.1705164","article-title":"Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).","volume":"36","author":"Myers","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R30-5-20210227","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"R31-5-20210227","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1399-3062.2009.00414.x","article-title":"Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.","volume":"11","author":"Park","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"R32-5-20210227","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R33-5-20210227","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1600-6143.2007.02134.x","article-title":"CD4 CD25 FOXP3 regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.","volume":"8","author":"Bloom","year":"2008","journal-title":"Am J Transplant"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0b013e31822ec296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:11:08Z","timestamp":1620965468000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201203000-00005"}},"subtitle":["An Institutional Experience"],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e31822ec296","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}